ARCH Venture Partners XII, LLC

Insider Reports History

Location
Chicago, IL
Signature
ARCH Venture Fund XII, L.P. By: ARCH Venture Partners XII, L.P., its General Partner By: ARCH Venture Partners XII, LLC, its General Partner By: /s/ Mark McDonnell, as Attorney-in-Fact
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by ARCH Venture Partners XII, LLC:

Company Role Class Num Shares Value Price $ Report Date Ownership
Rapport Therapeutics, Inc. 10%+ Owner Common Stock 3,728,738 $37,212,805 $9.98 10 Jun 2024 By ARCH Venture Fund XII, L.P.
Prime Medicine, Inc. 10%+ Owner Common Stock 6,128,297 $26,658,091 $4.35 01 Aug 2025 By ARCH Venture Fund X, L.P.
Prime Medicine, Inc. 10%+ Owner Common Stock 6,128,297 $26,658,091 $4.35 01 Aug 2025 By ARCH Venture Fund X Overage, L.P.
Neumora Therapeutics, Inc. 10%+ Owner Common Stock 12,205,379 $22,213,789 $1.82 27 Oct 2025 By ARCH Venture Fund X, L.P.
Neumora Therapeutics, Inc. 10%+ Owner Common Stock 11,886,758 $21,633,899 $1.82 27 Oct 2025 By ARCH Venture Fund X Overage, L.P.
Prime Medicine, Inc. 10%+ Owner Common Stock 6,230,300 $20,559,990 $3.30 01 Aug 2025 By ARCH Venture Fund XII, L.P.
Neumora Therapeutics, Inc. 10%+ Owner Common Stock 6,046,907 $15,782,427 $2.61 27 Oct 2025 By ARCH Venture Fund XII, L.P.
Neumora Therapeutics, Inc. 10%+ Owner Common Stock 2,321,566 $4,225,250 $1.82 27 Oct 2025 By ARCH Venture Fund VIII Overage, L.P.
Neumora Therapeutics, Inc. 10%+ Owner Common Stock 1,387,228 $2,524,754 $1.82 27 Oct 2025 By ARCH Venture Fund VII, L.P.
Metsera, Inc. Director, 10%+ Owner Common Stock 0 $0 $52.33 13 Nov 2025 Indirect
Metsera, Inc. Director, 10%+ Owner Series A Convertible Preferred Stock 0 03 Feb 2025 Indirect
Metsera, Inc. Director, 10%+ Owner Series B Convertible Preferred Stock 0 03 Feb 2025 Indirect
Metsera, Inc. Director, 10%+ Owner Series Seed Preferred Stock 0 03 Feb 2025 Indirect
Rapport Therapeutics, Inc. 10%+ Owner Series A Preferred Stock 0 10 Jun 2024 By ARCH Venture Fund XII, L.P.
Rapport Therapeutics, Inc. 10%+ Owner Series B Preferred Stock 0 10 Jun 2024 By ARCH Venture Fund XII, L.P.

Insider Reports Filed by ARCH Venture Partners XII, LLC

Symbol Company Period Transactions Value $ Form Type Role Filing Time
MTSR Metsera, Inc. 13 Nov 2025 2 $0 4 Director, 10%+ Owner 14 Nov 2025, 18:34
NMRA Neumora Therapeutics, Inc. 27 Oct 2025 1 +$4,999,977 4 10%+ Owner 29 Oct 2025, 19:21
PRME Prime Medicine, Inc. 01 Aug 2025 1 +$9,999,990 4 10%+ Owner 01 Aug 2025, 19:19
MTSR Metsera, Inc. 03 Feb 2025 9 +$39,999,996 4 10%+ Owner 03 Feb 2025, 19:01
MTSR Metsera, Inc. 30 Jan 2025 0 $0 3 10%+ Owner 30 Jan 2025, 21:25
RAPP Rapport Therapeutics, Inc. 10 Jun 2024 3 $0 4 10%+ Owner 10 Jun 2024, 19:46
RAPP Rapport Therapeutics, Inc. 06 Jun 2024 0 $0 3 10%+ Owner 06 Jun 2024, 19:14
PRME Prime Medicine, Inc. 15 Feb 2024 1 +$20,000,000 4 10%+ Owner 20 Feb 2024, 17:38
NMRA Neumora Therapeutics, Inc. 08 Dec 2023 2 $0 4 10%+ Owner 12 Dec 2023, 19:53
NMRA Neumora Therapeutics, Inc. 13 Nov 2023 2 +$412,140 4 10%+ Owner 15 Nov 2023, 18:54
NMRA Neumora Therapeutics, Inc. 08 Nov 2023 5 +$1,543,563 4 10%+ Owner 13 Nov 2023, 19:00
NMRA Neumora Therapeutics, Inc. 03 Nov 2023 3 +$1,099,945 4 10%+ Owner 07 Nov 2023, 18:59
NMRA Neumora Therapeutics, Inc. 28 Sep 2023 3 +$1,046,848 4 10%+ Owner 29 Sep 2023, 18:53
NMRA Neumora Therapeutics, Inc. 26 Sep 2023 2 +$700,464 4 10%+ Owner 27 Sep 2023, 20:18
NMRA Neumora Therapeutics, Inc. 22 Sep 2023 3 +$1,127,064 4 10%+ Owner 25 Sep 2023, 21:38